Research programme: cardiovascular diagnostic imaging - Pharmacyclics

Drug Profile

Research programme: cardiovascular diagnostic imaging - Pharmacyclics

Latest Information Update: 28 Nov 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmacyclics
  • Developer Johns Hopkins University School of Medicine; Pharmacyclics
  • Class Gadolinium-containing contrast agents; Texaphyrins
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Coronary artery disease

Most Recent Events

  • 04 Jun 2004 Pharmacyclics is looking for a collaborative partner for the programme
  • 03 Jun 2004 Preclinical trials in Coronary artery disease (diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top